Compare · NVO vs RARE
NVO vs RARE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Ultragenyx Pharmaceutical Inc. (RARE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RARE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 88.9x RARE ($2.16B).
- Over the past year, NVO is down 45.7% and RARE is down 41.7% - RARE leads by 4.0 points.
- RARE has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- Ultragenyx Pharmaceutical Inc.
- Price
- $41.01-4.51%
- $21.60-1.41%
- Market cap
- $191.82B
- $2.16B
- 1M return
- -10.44%
- -17.37%
- 1Y return
- -45.66%
- -41.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RARE
- Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
- Chief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)
- Director Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)
- Director Ray Amrit was granted 7,751 shares, increasing direct ownership by 33% to 31,116 units (SEC Form 4)
- Director Sanders Corazon (Corsee) D. was granted 7,751 shares, increasing direct ownership by 51% to 23,095 units (SEC Form 4)
- Director Narachi Michael was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)
- Director Welch Daniel G was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)
- Director Dunsire Deborah was granted 7,751 shares, increasing direct ownership by 25% to 38,566 units (SEC Form 4)